Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | CLK2 | P49760 | 3/20 | 0.49 |
| ▸ | GSK3A | P49840 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119639 | 0.91 | CDC7 (0.60) | SMN1; SMN2TSHRKDRPOLBMEN1 | |
| SCHEMBL29377513 | 0.91 | CDC7 (0.60) | SMN1; SMN2TSHRKDRPOLBMEN1 | |
| SCHEMBL20119970 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2TSHRKDRMEN1ALOX15 | |
| SCHEMBL20119679 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRKDRPOLBMEN1 | |
| SCHEMBL22524256 | 0.73 | STK3 (0.68) | TSHRKDRCYP1A2PRKD3MAP4K4 | |
| SCHEMBL20119638 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRPOLBMEN1KMT2A | |
| SCHEMBL2368308 | 0.71 | MAPK1 (0.65) | SMN1; SMN2TSHRPOLBMEN1ALOX15 | |
| SCHEMBL31301663 | 0.71 | STK3 (0.66) | KDRPRKD3MAP4K4PRKACACLK2 | |
| SCHEMBL31301756 | 0.70 | STK3 (0.61) | KDRPRKD3MAP4K4PRKACACLK2 | |
| Kinetin SCHEMBL15705 | 0.70 | SMN1; SMN2 (0.66) | SMN1; SMN2TSHRKDRPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885TSHR 4371/4885KDR 3757/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885TSHR 4371/4885KDR 3757/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885TSHR 4371/4885KDR 3757/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885TSHR 4371/4885KDR 3757/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885TSHR 4371/4885KDR 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.